Trials / Unknown
UnknownNCT04717999
Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma
Pilot Study of UWNKG2D CAR-T in Treating Patients With Recurrent Glioblastoma
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- UWELL Biopharma · Industry
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a pilot phase I study to evaluate the safety and efficacy of NKG2D CAR-T cell therapy in patients with relapsed and/or refractory glioblastoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NKG2D CAR-T | The NKG2D CAR-T will be administrated via intracerebroventricular injection through an Ommaya catheter. Standard treatments such as temozolomide will be stopped during the infusion of NKG2D CAR-T. |
Timeline
- Start date
- 2021-09-01
- Primary completion
- 2023-09-30
- Completion
- 2023-12-31
- First posted
- 2021-01-22
- Last updated
- 2021-01-22
Source: ClinicalTrials.gov record NCT04717999. Inclusion in this directory is not an endorsement.